Skip to main content
Clinical Trials/NCT00434759
NCT00434759CompletedNot Applicable

Evaluation of the Efficacy, Mechanisms of Change and Efficiency of a Stepped-care Program With a Computer-based Self-help Module and Minimal Therapist Contact in Comparison to a Standard Cognitive Therapy for Patients With Social Phobia

Central Institute of Mental Health, Mannheim2 sites in 1 country89 target enrollmentStarted: September 1, 2006Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
89
Locations
2
Primary Endpoint
Change From Baseline in Social Interaction Anxiety Scale (SIAS)

Study Overview

Brief Summary

Primary objective:

The purpose of this study is to examine efficacy and efficiency of a Stepped Care Program (SCP) for patients with Social Phobia in comparison to the standard cognitive therapy for Social Phobia according to D.M. Clark.

Secondary objective:

Further, it is intended to identify mechanisms of change which mediate treatment outcome and to identify differential predictors for therapy success for the two treatment conditions.

Detailed Description

With prevalence rates (lifetime) up to 13% in western countries, Social Phobia is one of the most frequent mental disorders. Main objective of this clinical trial is the evaluation of the efficacy and efficiency of a stepped care program for patients with Social Phobia (SCP) as compared to a standard therapy (ST) for patients with social phobia. Both interventions are based on the cognitive therapy according to D.M. Clark.

The SCP starts with a 8-sessions self-help-module with minimal therapist contact via email. Patients who do not reach remission after this first step, enter step 2 which consists of 8 therapy sessions guided by a therapist. If patients are not remitted after that, they receive another 8 sessions of therapist-guided cognitive treatment in step 3. So the SCP contains 8, 16 or 24 sessions of therapy - depending on remission status of the patient. In contrast to that, the ST comprises 16 sessions of therapist-guided intervention.

The diagnostic status of the patients is assessed by blinded clinician raters before treatment, after every eighth therapy session, and at 5 follow-up timepoints in order to examine the stability of treatment effects (3, 6, 9, 12 and 30 months after the end of therapy). Besides efficacy and efficiency of the SCP vs. ST, mechanisms of change and differential predictors for therapy outcome will be investigated.

Hypotheses: We expect that

  1. the SCP is significantly more effective than the ST.
  2. the SCP is significantly more efficient than the ST.
  3. the results referring to the efficacy will be stable up to 30 months after the end of treatment(Follow Up Phase).
  4. the SCP will cause less primary and secondary costs than the ST.
  5. successful therapy leads to an improvement in the following areas:

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Single (Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 60 Years (Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosis of Social Phobia according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders IV (DSM-IV)
  • Duration of the disorder at least 1 year
  • Severity of symptomatology according to at least one of two self-report measures for social anxiety above Cut-Off: Social Interaction Anxiety Scale (SIAS: value of 26 or more) and / or Social Phobia Scale (SPS: value of 17 or more)
  • Age: 18-60
  • Written Informed Consent

Exclusion Criteria

  • Social Phobia is not the main diagnosis
  • Mental Retardation
  • Lifetime Diagnoses: Schizophreniform Disorder, Bipolar Affective Disorder
  • Acute Diagnoses: severe Major Depression Episode, severe Anorexia Nervosa, Substance-, Drug - or Alcohol-Dependence, life-threatening suicidal crisis
  • Psychotropic medication (except stable treatment with antidepressant since 3 months before study start: medication and dosage has to be stable during the entire study duration)

Outcomes

Primary Outcomes

Change From Baseline in Social Interaction Anxiety Scale (SIAS)

Time Frame: baseline to post-treatment (on average 24 weeks)

This scale measures interaction anxiety on a 5-point scale (range of scores is 0-4); the number of items is 20; the total minimum for all 20 items is 0 and the total maximum is 80; lower values consider better outcome.

Change From Baseline in Social Phobia Scale (SPS)

Time Frame: baseline to post-treatment (on average 24 weeks)

The scale measures social anxiety on a 5-point scale (range of score is 0-4) ; the number of items is 20; the total minimum for all 20 items is 0 and the total maximum is 80; lower values consider better outcome.

Change From Baseline in Liebowitz Social Anxiety Scale (LSAS)

Time Frame: baseline to post-treatment (on average 24 weeks)

The scale measures social anxiety and avoidance on a 4-point-scale (range of scores is 0-3). Blinded raters assessed social anxiety and avoidance behaviour relating to 24 social situations. Minimum for all 24 situations is 0, maximum for all 24 situations including the assessments for anxiety and avoidance is 144). Lower scores consider better outcome.

Secondary Outcomes

  • Change From Baseline in Brief Symptom Inventory (BSI)(baseline to post-treatment (on average 24 weeks))
  • Change on Baseline in Center for Epidemiologic Studies Depression Scale (CES-D)(baseline to post-treatment (on average 24 weeks))

Investigators

Sponsor
Central Institute of Mental Health, Mannheim
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (2)

Loading locations...

Similar Trials